Absci (NASDAQ:ABSI) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Posted by Renee Jackson on Mar 19th, 2025

Absci (NASDAQ:ABSI – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.03), Zacks reports. The business had revenue of $0.67 million during the quarter, compared to analyst estimates of $1.77 million. Absci had a negative net margin of 2,321.56% and a negative return on equity of 46.56%.

Absci Stock Down 4.0 %

Shares of ABSI opened at $3.08 on Wednesday. The company has a 50-day simple moving average of $3.87 and a 200-day simple moving average of $3.68. The firm has a market capitalization of $353.76 million, a P/E ratio of -3.31 and a beta of 2.09. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63. Absci has a 52 week low of $2.45 and a 52 week high of $6.72.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. KeyCorp cut their target price on shares of Absci from $6.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Guggenheim reissued a “buy” rating and set a $10.00 target price on shares of Absci in a research report on Tuesday, December 3rd. Needham & Company LLC assumed coverage on shares of Absci in a research report on Wednesday, January 22nd. They set a “buy” rating and a $9.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Absci in a research report on Friday, January 17th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Absci has an average rating of “Buy” and an average price target of $8.57.

Get Our Latest Analysis on ABSI

About Absci

(Get Free Report)

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.